Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Drug Manufacturers - Specialty & Generic

Healthcare
$28.96 +1.17%

+$0.51 today

Market cap
$6.02B
Beta
0.54
P/E (TTM)
-87.6
EPS (TTM)
-$0.50
52W Low $30.83High $59.68

Volume 2.71M

Average 0.64M

SUPN Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Supernus Pharmaceuticals, Inc.NASDAQ: SUPN

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue growth accelerates

Q2 FY2026 revenue of $219.06M rose 32.4% year over year, ahead of the +24.9% change in trailing-twelve-month revenue. Sequentially, it rose 5.5% from the prior quarter. Over 3 fiscal years it compounded at +2.5% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 1 analysts of $1.69B (+135.6%) for the fiscal year ending Dec 2026, a step up from the +8.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$219.06M+5.5% QoQ
Last fiscal yearDec 2025
$718.95M+8.6% YoY
LTMJun 2026
$830.44M+24.9% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.4%+71.4%+39.0 pp
1 year+8.6%+135.6%+127.0 pp
3-year CAGR+2.5%+53.1%+50.6 pp
5-year CAGR+32.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
718.95M USD
Year-over-year change
+8.6%
4-year CAGR
+5.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How SUPN compares with its peers on the latest reported figures

  • SUPN's LTM Jun 2026 revenue of $830.44M is the 2nd highest of the 3 companies compared; the peer median is $1.27B.
  • Its year-over-year change of +24.9% is the highest of 3, against a peer median of +17.6%.
  • Over three fiscal years its annual growth of +2.5% compares with a peer median of +14.4%.
SUPN Competitors Peer median
Revenue for SUPN and competitors
Company Period LTM YoY 3-year CAGR
ALKSAlkermes plcLTM Sep 2026$1.75B +15.3%+9.9%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$830.44M +24.9%+2.5%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$796.33M +19.9%+18.9%
Peer median (excluding SUPN) $1.27B+17.6%+14.4%

Competitors are the stored peer set for SUPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue579.78M667.24M607.52M661.82M718.95M
Cost of Revenue75.06M87.22M83.78M77.91M74.56M
Gross Profit504.71M580.02M523.74M583.91M644.39M
Gross Margin87.1%86.9%86.2%88.2%89.6%
Research & Development90.47M74.55M91.59M108.8M106.24M
Selling, General & Admin304.76M377.22M336.36M335.78M485.56M
Operating Expenses418.69M533.89M529.01M502.25M681.25M
Depreciation & Amortization32.6M85.54M84.86M80.41M91.56M
EBITDA129.19M153.36M90.04M178.28M42.53M
EBITDA Margin22.3%23.0%14.8%26.9%5.9%
Operating Income86.03M46.12M(5.27M)81.67M(36.86M)
Operating Margin14.8%6.9%-0.9%12.3%-5.1%
Interest Income10.57M21.69M10.45M16.2M13.25M
Interest Expense23.42M7.07M2.42M00
Other Income / Expenses(12.85M)14.62M8.04M16.2M(12.17M)
Income Before Tax73.18M60.74M2.77M97.87M(49.03M)
Pre-Tax Margin12.6%9.1%0.5%14.8%-6.8%
Income Tax Expense19.75M32K1.45M24.01M(10.48M)
Net Income53.42M60.71M1.32M73.87M(38.55M)
Net Margin9.2%9.1%0.2%11.2%-5.4%
EPS (Basic)1.011.130.021.34(0.68)
EPS (Diluted)0.981.040.021.32(0.68)
Weighted Avg Shares53.1M53.67M54.54M55.1M56.45M
Weighted Avg Shares (Diluted)54.36M61.68M55.51M55.96M56.45M

Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Intrinsic Alpha fair value

Locked

Current Price

$28.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.